Kristen Seaver is a Managing Director at WilliamsMarston LLC, with over 20 years of valuation advisory experience. Her expertise covers a wide range of financial reporting matters, including mergers and acquisitions, purchase price allocations, goodwill and intangible asset impairments, stock-based compensation, complex debt and equity instruments, and tax reporting matters such as 409a valuations, as well as litigation matters, solvency, and fairness opinions. Kristen's industry experience spans technology, life sciences, consumer products, and more. Before joining WilliamsMarston, she served as a Managing Director at Bay Valuation Advisors, LLC, advising clients from early-stage ventures to Fortune 100 companies on complex valuations. Earlier in her career, she was a Senior Manager at Deloitte LLP, where she managed valuation projects for key clients in the technology and life sciences sectors. Kristen also worked in valuation and transfer pricing at other Big 4 firms. She is a Chartered Financial Analyst® and holds an MBA from Georgia Institute of Technology and a BA in Economics from Emory University.
Current trends are driven by various strategic and financial considerations from both established pharmaceutical companies and development-stage biotech firms. Understanding the valuation and accounting implications of these transactions are crucial for stakeholders to navigate the complex landscape effectively.